Our products are for in vitro research use only, not for clinical diagnosis
-
ProductWe specialize in the development, production and sales of ELISA kits, antibodies, recombinant proteins and related reagents for the international market.
-
ResearchThe company has mature biological technologies such as molecular biology technology, immunology technology, protein expression and purification technology, antibody screening and preparation.
-
ServicesWith excellent products and perfect service system, the company is favored and recognized by the majority of domestic and foreign customers.
-
NewsThe company would like to be your research helper and professional manufacturer.
-
AboutLocated in China Optics Valley Biological City, the company has a modern R&D center and a standard production workshop, and has passed the overall ISO 9001:2022 quality management system certification.
HTRA activator plays a therapeutic role in papain-induced lung inflammation by limiting ILC activation
Time：
2023-06-14
HTR2A agonists play a therapeutic role by restricting ILC2 activation in papain-induced lung inflammation
HTRA agonists play a therapeutic role in papain-induced lung inflammation by limiting ILC activation
HTR2A agonists play a therapeutic role by restricting ILC2 activation in papain-induced lung inflammation
Reports of specific drug targets against group 2 innate lymph-like cells ((ILC2) in the lung are relatively rare. Earlier studies have shown that one can ameliorate papain-induced lung inflammation by inhibiting the activation of ILC2. In the present study, we found that HTR2A selective activator (DOI) can limit the activation of ILC2 and attenuate the ILC2-mediated type 2 immune response, whereas the small organelle with w-specific deletion of the HIR2A site produced no 00-mediated inhibition of 102s in papain-reading-induced small-needed capital therapy camphor phenotype, and the present study suggests that DOI can limit the type 2 pulmonary immune response, while acting on The drug target of HTR2A receptor on ST2+ILC2 may become a new therapeutic strategy for type 2 pneumonia.
IF22.096
Author Affiliation.
State Key Laboratory of Cell Biology, University of Chinese Academy of Sciences, China
Published in:CellularMolecularImmunology
DOI:101038/s41423-023-0098-6
Product index & item number.
Enhanced Cell Counting Kit8(WST-8/CCK8)(E-CK-A362)
More Guides
Contact Us
Phone： 400-027-8858
Fax： 027-86627593
Address：A101, Building C1, Bio City, No.666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan
E-mail：reivaa@reivaa.com
Copyright © 2023Wuhan Reivaa Biotech Co., Ltd.
SEO | Business license | IPv6 access support
IPv6 access support
WhatsApp：400-027-8858
Add：A101, Building C1, Bio City, No.666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan
E-mail： mail@reivaa.com
We will give you feedback in time